Arvin C. Dar, Ph.D.
Affiliations: | Structural and Chemical Biology | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Website:
http://www.mountsinai.org/profiles/arvin-darGoogle:
"Arvin Christopher Dar"Bio:
Mean distance: 8.2 | S | N | B | C | P |
Parents
Sign in to add mentor| Frank Sicheri | grad student | 2006 | University of Toronto | |
| (Catalytic switching and substrate recognition mechanisms of the RNA dependent protein kinase PKR) | ||||
| Kevan Michael Shokat | post-doc | 2006-2011 | UCSF | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Marsiglia WM, Chow A, Khan ZM, et al. (2023) Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes. Nature Chemical Biology |
| Rialdi A, Duffy M, Scopton AP, et al. (2023) WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nature Cancer |
| Chow A, Khan ZM, Marsiglia WM, et al. (2022) Conformational control and regulation of the pseudokinase KSR via small molecule binding interactions. Methods in Enzymology. 667: 365-402 |
| Smith RHB, Khan ZM, Ung PM, et al. (2021) Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα. Biochemistry |
| Khan ZM, Real AM, Marsiglia WM, et al. (2020) Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature |
| Yu JX, Craig AJ, Duffy ME, et al. (2019) Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as targets for HCC polypharmacology. Molecular Cancer Therapeutics |
| Huang KL, Wu Y, Primeau T, et al. (2019) Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability. Molecular & Cellular Proteomics : McP |
| Ung PMU, Sonoshita M, Scopton AP, et al. (2019) Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network. Plos Computational Biology. 15: e1006878 |
| Sonoshita M, Scopton AP, Ung PMU, et al. (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nature Chemical Biology |
| Dhawan NS, Scopton AP, Dar AC. (2016) Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature |